This move is archived. Current quotes and coverage live on the stock page.
Get BLCO alerts:
Bausch + Lomb Corp faces a challenging trading day as its stock slips significantly.
Bausch + Lomb Corp (BLCO.TO) is seeing a notable decline in its stock price today, down 2.60% to CA$22.10. This drop comes despite recent product launches and market developments that haven’t yet built investor confidence.
Advertisement
Bausch + Lomb Corp
BLCO.TO
BLCO.TO
Bausch + Lomb Corp
WealthAwesomeMarket cap
$8.87B
52W high
$25.70
52W low
$19.36
1W change
+5.17%
Beta
0.55
Analyst Price Targets
Based on analyst covering BLCO
Wall Street analysts forecast BLCO stock price to rise 1.0% over the next 12 months.
Consensus
NeutralBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$25.07
+1.0% Upside
Current Price
C$24.83
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BLCO's historical volatility
30-Day Vol
21.8%
Annualized
90-Day Vol
27.5%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$29.68
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$26.35 | C$24.45 – C$28.41 |
| 60 trading days | C$27.97 | C$25.15 – C$31.10 |
| 90 trading days | C$29.68 | C$26.07 – C$33.81 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should be cautious as Bausch + Lomb's recent product introductions have not eased market concerns, leading to a significant stock decline today.
Bausch + Lomb Corp's stock down 2.60% today
The stock has dropped 4.8% year-to-date, contrasting sharply with the broader market's performance.
Bull case
Bausch + Lomb's recent launch of the EyeGility Inserter could strengthen its position in the ophthalmic surgical devices sector. This innovation may lead to improved sales and boost investor confidence over time.
Bear case
The current decline in stock price reflects broader investor skepticism, particularly as the company’s performance lags behind industry peers. This raises concerns about its growth trajectory.
Advertisement
Market Reaction to Recent Developments
Despite the recent launch of the EyeGility Inserter, aimed at streamlining cataract surgeries, Bausch + Lomb's stock is sliding today. The market seems to be reacting negatively, with shares down 3.3% since the announcement of the new product. This raises questions about whether these innovations are enough to drive sales or improve investor sentiment.
Comparative Performance and Investor Sentiment
Bausch + Lomb's stock has underperformed compared to its industry, with a year-to-date decline of 4.8% versus a modest 0.7% decline in the sector. This disparity highlights growing concerns among investors about the company's growth prospects and competitive positioning in the eye health market. The current sentiment is further compounded by the company's Zacks Rank of #4 (Sell), indicating a cautious outlook.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
